http://www.biospace.comBioSpace RSS GeneratorWed, 19 Jun 2013 11:58:08 GMT20http://rss.biospace.com/images/BSPLogo.gifhttp://www.BioSpace.com/news.aspx?SectionId=1Copyright (C) 2011http://www.rttnews.com/2128928/sanofi-reports-phase-3-topline-trial-results-of-iniparib-otamixaban.aspx?type=bnStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Sanofi (SAN)s experimental cancer treatment iniparib failed to help lung-cancer patients in a late-stage trial, prompting the company to end research into the once-promising compound and take a $285 million...Tue, 04 Jun 2013 12:00:00 AM GMThttp://www.thepharmaletter.com/file/121896/bayer-drops-hemophilia-candidate-bay-86-6150-on-safety-concerns.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Bayer said its HealthCare division stopped a Phase II/III study testing its experimental treatment BAY 86-6150 on certain haemophilia A and B patients due to safety concerns.<br><br>Help employers...Tue, 07 May 2013 12:00:00 AM GMThttp://www.bloomberg.com/news/2013-04-18/celltrion-drops-late-stage-trial-of-roche-rituxan-drug-copy.htmlCelltrion Inc. (068270) dropped a late-stage trial of a biosimilar version of Roche Holding AG (ROG)s best-selling Rituxan drug, potentially benefiting competitors such as Boehringer Ingelheim GmbH and Novartis (NOVN) AG. Celltrion had planned to take its drug, CT-P10, into phase- III trials later this year, Asthika Goonewardene, a London-based analyst for Bloomberg Industries, wrote in a note today...Fri, 19 Apr 2013 12:00:00 AM GMThttp://www.thepharmaletter.com/file/121094/clavis-pharma-stops-elacytarabine-development-on-negative-ph-iii-trial-in-acute-myeloid-leukemia.htmlClavis Pharma ASA (CLAVIS), a Norwegian biotech, is considering closing or selling itself to another company after its experimental leukemia treatment elacytarabine failed in a late-stage trial. Clavis has a short-list of Scandinavian private companies that may be interested in taking it over and will approach them over the next few weeks, Chief Executive Officer Olav Helleboe said on a conference...Wed, 03 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291057&full=1JERUSALEM--(BUSINESS WIRE)-- BioLineRx (BLRX) (BLRX.TA), a biopharmaceutical development company, today announced that results from a pre-planned interim analysis of the Phase II/III CLARITY trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, indicate that the trial would not meet the pre-specified primary efficacy endpoint. After conferring...Thu, 21 Mar 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20130311005504&newsLang=enSTOCKHOLM--(BUSINESS WIRE)--Regulatory News: Moberg Derma AB (STO:MOB) has decided to discontinue the development of Limtop - a drug candidate for the treatment of actinic keratosis. The decision is based on data from a completed phase II clinical trial, where the efficacy of Limtop did not reach the predefined target. "Based on data from the completed study, we deem that the project's commercial potential...Mon, 11 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=287386&full=1Brussels (Belgium), 11 February 2013 - 7:00 AM (CET) regulated information - UCB and its partner, Amgen Inc., have decided to not pursue a phase 3 clinical trial program for CDP7851/AMG785 (romosozumab) in acceleration of fracture healing based on the evaluation of currently available Phase 2 results from accelerated fracture healing studies and general regulatory guidance on fracture healing programs...Wed, 13 Feb 2013 12:00:00 AM GMThttp://www.thestreet.com/story/11780088/1/ranbaxy-halts-production-of-generic-lipitor-hot-trends.htmlRanbaxy Laboratories Ltd. has stopped production of its generic version of cholesterol-lowering drug Lipitor as the company investigates what caused tiny glass particles to appear in some bottles, triggering a large recall earlier this month. Details also emerged Thursday of a smaller recall of Ranbaxy's generic Lipitor in August, over a potential pill mix-up. The U.S. Food and Drug Administration...Mon, 03 Dec 2012 12:00:00 AM GMThttp://www.healio.com/cardiology/chd-prevention/news/online/%7B1E0CA070-F85D-4CEB-9AF9-2B1D61098BF5%7D/Dalcetrapib-increased-HDL-did-not-reduce-risk-for-CV-eventsRoche Holding AG (ROG)s abandoned heart drug dalcetrapib, designed to raise levels of good cholesterol, also boosted blood pressure and inflammation, researchers said. Dalcetrapib marks the second failure in what was expected to be a new blockbuster class of heart medicines known as CETP inhibitors. The Basel, Switzerland-based drugmaker halted development of the drug in May, saying an early look...Wed, 07 Nov 2012 12:00:00 AM GMThttp://www.bizjournals.com/washington/news/2012/10/11/novartis-drops-long-acting-version-of.html?ana=otjrssWashington Business Journal by Bill Flook, Staff Reporter </p><p>Novartis Pharma AG is discontinuing development on a long-acting injectable version of Vanda Pharmaceuticals Inc.s Fanapt, the District-based biotech reported in a securities filing.</p><p>Novartis has marketed Fanapt, a schizophrenia drug and Vandas lead product, since 2010. The pharma giant has exclusive rights to develop...Fri, 12 Oct 2012 12:00:00 AM GMTOxford, UK 10 October 2012: Oxford BioMedica (Oxford BioMedica or the Company) (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that it plans to close the Phase II study in the United States (US) to assess the activity of TroVax (MVA-5T4) in patients with progressive hormone refractory prostate cancer (HRPC). TroVax continues to have an active Phase II development...Thu, 11 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=275195&full=1PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its collaboration partner GlaxoSmithKline (GSK) has discontinued clinical development of GSK2251052. As previously disclosed, GSK halted the most recent clinical trials of GSK2251052 due to the identification of microbiological findings of resistance in a small number of patients in the Phase 2b trial for...Mon, 08 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=274704&full=1WOBURN, Mass. & TOKYO--(BUSINESS WIRE)-- ArQule, Inc. (ARQL) and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that the independent Data Monitoring Committee (DMC) of the Phase 3 MARQUEE (Met inhibitor ARQ 197 plus Erlotinib vs Erlotinib plus placebo in NSCLC) trial recommended the study be stopped early following a planned interim analysis, when they concluded that the study would not meet...Wed, 03 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=274468&full=1September 28, 2012 - Novo Nordisk today announced the decision to discontinue the development ofvatreptacog alfa, a fast-acting recombinant factor VIIa analogue for haemophilia patients with inhibitors. The decision follows analysis of the data from the phase 3a trial adeptTM 2. On 9 August, Novo Nordisk announced that a few patients in the trial had developed anti-drug antibodies to vatreptacog...Tue, 02 Oct 2012 12:00:00 AM GMThttp://www.nasdaq.com/article/lundbeck-to-halt-sale-of-leukemia-drug-citing-supply-problems-20120913-00984H. Lundbeck A/S (LUN.KO) plans to stop selling a leukemia treatment because of manufacturing and supply difficulties. Denmark-based Lundbeck "is no longer in a position to guarantee a future supply" of the drug Elspar, Roger Keding, vice president of supply chain management, said in an Aug. 3 letter to U.S. health-care providers. "Lundbeck has concluded that continuing to manufacture and distribute...Mon, 17 Sep 2012 12:00:00 AM GMThttp://www.rttnews.com/1961429/palatin-says-partner-astrazeneca-to-stop-further-azd2820-drug-development.aspx?type=bn&utm_source=google&utm_campaign=sitemapCRANBURY, N.J.</span>, <span class"xn-chron">Sept. 7, 2012</span> /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that its collaboration partner, AstraZeneca, has decided to discontinue further development of AZD2820, one of a number of collaboration compounds in various stages of development for the treatment of obesity. AstraZeneca remains committed to this collaboration...Mon, 10 Sep 2012 12:00:00 AM GMThttp://www.nytimes.com/2012/08/24/business/bristol-myers-ends-work-on-hepatitis-c-drug.htmlBristol-Myers Squibb said Thursday that it was discontinuing development of a hepatitis C drug that it had acquired in a $2.5 billion deal, after nine patients in a clinical trial had to be hospitalized and one of them died. The company suspended testing of the drug on Aug. 1, after one patient in a midstage clinical trial experienced heart failure. At that time, however, there was still some question...Mon, 27 Aug 2012 12:00:00 AM GMThttp://www.foxbusiness.com/news/2012/06/05/bioinvent-thrombogenics-cancel-development-drug-candidate/LEUVEN, <span class"xn-location">Belgium</span> and <span class"xn-location">LUND, Sweden</span>, <span class"xn-chron">June 5, 2012</span> /PRNewswire/ --</p><p>- All further development of TB-402 will be stopped</p><p>ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today the results from a Phase IIb trial comparing TB-402, a long...Tue, 05 Jun 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=256684&full=1UPPSALA, Sweden--(BUSINESS WIRE)--Macrolane is a safe and well-tolerated injectable product used to augment body contour and correct soft tissue defects. Introduced in 2008, it has improved the quality of life of thousands of patients in indications ranging from HIV-related lipoatrophy to breast augmentation. A safety reporting system has been in place since launch and no safety concerns have been...Tue, 17 Apr 2012 12:00:00 AM GMThttp://uk.ibtimes.com/articles/260098/20111202/sanofi-discontinues-selling-lovenox-authorized-generic.htmSanofi SA (NYSE: SNY) said in a letter sent to customers dated Nov. 30 that it has discontinued selling the Authorized Generic version of Lovenox (Enoxaparin). "We note that Sanofi's decision to discontinue the Authorized Generic was largely expected following a federal court injunction preventing sales of Amphastar's generic Enoxaparin," said Duane Nash, an analyst at Wedbush Securities. In sum, Lovenox...Mon, 05 Dec 2011 12:00:00 AM GMThttp://www.nytimes.com/2011/11/26/health/research/anti-hiv-gel-trial-is-canceled-in-africa.htmlNovember 25, 2011 -- A large-scale clinical trial evaluating whether daily use of an antiretroviral-containing oral tablet or vaginal gel can prevent HIV infection in women is being modified because an interim review found that the gel, an investigational microbicide, was not effective among study participants. </p><p>On Nov. 17, an independent data and safety monitoring board (DSMB) recommended...Tue, 29 Nov 2011 12:00:00 AM GMThttp://www.reuters.com/article/2011/11/22/celgene-idUSN1E7AL1WH20111122BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Srl, a subsidiary of Celgene Corporation, (NASDAQ: CELG - News) announced that based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients...Mon, 28 Nov 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=238078&full=1STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Moberg Derma AB (OMX: MOB) has decided to discontinue the preclinical program for the drug candidate for treatment of anal fissures - A-Fizz. The decision to discontinue was made since the validating preclinical results did not fulfill the companys criteria. </p><p>It is a disappointment to discontinue the development program but our product candidates...Thu, 27 Oct 2011 12:00:00 AM GMThttp://www.reuters.com/article/2011/10/07/takeda-idUST9E7KS00T20111007Takeda Pharmaceutical said on Friday it would discontinue development of insomnia drug ramelteon in Europe, after feedback on development requirements from the region's regulatory body. The drug, available as Rozerem in the United States and Japan, was once seen as a promising source of income for the Japanese firm, but sales never took off as expected because some patients found its effects were not...Mon, 10 Oct 2011 12:00:00 AM GMThttp://www.reuters.com/article/2011/09/28/astellas-idUSL3E7KS17D20110928?feedType=RSS&feedName=companyNews&rpc=43Japan's Astellas Pharma said it halted the global development of the experimental anti-clotting drug darexaban maleate, or YM150, after a study raised questions about its role in treating patients with heart problems. The drugmaker said in a statement on Wednesday that it stopped development of the new oral anticoagulant amid increasing competition and after it was unable to find a partner to help...Thu, 29 Sep 2011 12:00:00 AM GMThttp://www.xconomy.com/san-diego/2011/08/04/amylin-takeda-halt-obesity-drug-development/OSAKA, Japan</span>, <span class"xn-chron">Aug. 5, 2011</span> -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that they are discontinuing development of pramlintide/metreleptin, an investigational combination therapy for the treatment of obesity that comprises pramlintide, an analog of the natural hormone amylin, and metreleptin...Mon, 08 Aug 2011 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20110718_1July 18, 2011 -- Beijing BeiLu Pharmaceutical decided to end its agomelatine development project. The company said the SFDA refused to authorize a clinical trial of agomelatine, an antidepressant drug, saying the IND filing did not prove the drug was effective. BeiLu explained that a new application for a clinical trial would take three years, which it feels would cause the company to miss the most...Tue, 19 Jul 2011 12:00:00 AM GMThttp://www.genengnews.com/gen-news-highlights/lack-of-partner-prompts-genmab-to-sideline-late-stage-cancer-antibody/81245346/Genmab A/S (Copenhagen:GEN) announced today it will wind down the zalutumumab clinical program. After an extensive search during the first half of the year, the company has not found a satisfactory partnership to take zalutumumab forward in the current climate. As part of the company's disciplined approach and commitment to controlling costs, Genmab will wind down the zalutumumab program. Genmab will...Tue, 28 Jun 2011 12:00:00 AM GMThttp://www.genengnews.com/gen-news-highlights/diamyd-discontinues-u-s-phase-iii-trial-with-type-i-diabetes-product/81245338/STOCKHOLM, Jun 23, 2011 (BUSINESS WIRE) -- Regulatory News: Diamyd Medical AB (sto:DIAMB) reports that the Company has decided to suspend dosing in a US Phase III study with the antigen-based therapy Diamyd(R) and to initiate closure of the study. </p><p>Following consultation with the US Food and Drug Administration (FDA), Diamyd Medical has decided to suspend dosing in its US Phase III study...Fri, 24 Jun 2011 12:00:00 AM GMThttp://www.kktv.com/home/headlines/Drugmakers_Eliminate_Infant_Drops_of_Key_Medicine_121293999.html?storySection=commentsJohnson & Johnson and other makers of cold and fever medications said Wednesday that they will discontinue infant drops of medicines containing acetaminophen in an effort to avoid confusion that can lead to dangerous overdoses. The industry association for over-the-counter medicine companies said its members will begin phasing out the liquid drops later this year. After the transition is complete...Thu, 05 May 2011 12:00:00 AM GMThttp://www.pharmalot.com/2011/03/mon-dieu-france-rejects-astrazeneca-bloodthinner/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Pharmalot+%28Pharmalot%29Pharmalot -- Just three months after the FDA rejected the new Brilinta bloodthinner from AstraZeneca, France is now reportedly giving the drugmaker a hard time as well. Even though the European Medicines Agency already endorsed the treatment, the HAS health technology assessment agency in France has decided the med has an unfavorable risk/benefit profile, which puts a halt to final pricing talks and...Thu, 24 Mar 2011 12:00:00 AM GMThttp://online.wsj.com/article/BT-CO-20110215-704422.htmlPARIS (Dow Jones)--French pharmaceutical group Sanofi-Aventis SA (SNY) is withdrawing its anti-nausea drug Anzemet from the markets in five of the 13 countries in which it is sold, a spokeswoman said Tuesday. Tue, 15 Feb 2011 12:00:00 AM GMTPARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN, ADR: IPSEY) announced today that the preliminary data from the ongoing phase IIb study in patients with acromegaly for its chimeric compound BIM 23A760 does not meet the expected inhibition of growth hormone (GH) and IGF-1 levels after repeat dosing. Preliminary phase IIb data showed a strong dopaminergic activity but only weak evidence...Wed, 15 Dec 2010 12:00:00 AM GMThttp://www.thepharmaletter.com/file/95109/rochebiogen-drop-development-of-ocrelizumab-in-rheumatoid-arthritis.htmlBASEL, Switzerland & CAMBRIDGE, Mass., May 19, 2010 (BUSINESS WIRE) -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Biogen Idec /quotes/comstock/15*!biib/quotes/nls/biib (BIIB 50.70, 0.13, 0.26%) today announced their decision to discontinue the ocrelizumab clinical development programme in patients with rheumatoid arthritis (RA).</p><p>Following a detailed analysis of the efficacy and safety results...Wed, 19 May 2010 12:00:00 AM GMThttp://www.reuters.com/article/marketsNews/idINLT61617820090429?rpc=44 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Wed, 29 Apr 2009 12:00:00 AM GMThttp://www.reuters.com/article/marketsNews/idINLH52983720081117?rpc=44BRUSSELS, Nov 17 (Reuters) - Belgian drugs, chemicals and plastics maker Solvay said on Monday it was ending its research into a compound for the treatment of obesity.Mon, 17 Nov 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=112298&full=1<p> COPENHAGEN, October 8 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that it is discontinuing development of zanolimumab (HuMax-CD4(R)). In addition, as a result of a portfolio review and assessment of the organization, Genmab is reducing its headcount by 101 positions.</p><p> As the company approaches potential commercialization, the need to establish a sustainable level...Wed, 08 Oct 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=112027&full=1<b><img src"http://enewsletters.biospace.com/images/columnists/suvarnabhatt.jpg" width"100" height"123" hspace"5" vspace"3" align"left" />Life Science Weekly inSite (Sep. 29 - Oct. 3)</b><br>A weekly round-up of biotech's top stories from around the world<br>By <a href"http://www.biospace.com/community/persona.aspx?plckPersonaPagePersonaProfile&plckUserId482383&bioId482383&sidsitelife.biospace...Mon, 06 Oct 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=103438&full=1PARIS--(MARKET WIRE)--Jul 16, 2008 -- BioAlliance Pharma suspends the Phase II/III trial of doxorubicin Transdrug in primary liver cancer, following advice from the Drug Safety Monitoring Board and the Steering Committee</p><p>Paris, July 16th, 2008 - BioAlliance Pharma SA (Euronext Paris -BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer...Wed, 16 Jul 2008 12:00:00 AM GMT